Orphazyme
New therapies for the treatment of rare and genetic diseases
Orphazyme has raised €34M across 3 funding rounds from 4 investors, most recently a Series B round in Jan 2015. Based in Copenhagen, Denmark; founded 2009; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€34M
€33,608,559
Funding rounds
3
Investors
4
distinct backers
Active since
2011-02
latest 2015-01
Funding by year
EUR raised per yearOrphazyme — funding by year — interactive chart.
Data table
| Orphazyme — funding by year | |
|---|---|
| 2011 | €14M |
| 2014 | €20M |
Signals
High confidenceRaise-next likelihood11
base rate 48% for Series B
- ▼ Dormant (no round in 3+ cohort gaps)
- ▲ Up-round momentum
Exit likelihood8
base rate 11% (2+ rounds)
- ▲ €30M+ raised
- ▼ Old (17y) — past typical exit age
- ▼ No recent equity round (debt-only or quiet)
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
3 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2015-01-01 | Series B | €20M | Aescap,IDInvest Partners,Sunstone Capital | View deal → |
| 2011-09-01 | Series A | €14M | Aescap,Novo Holdings,Sunstone Capital | View deal → |
| 2011-02-01 | Seed | €0 | Novo Holdings,Sunstone Capital | View deal → |
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
- Oura Health€779MFinland · Healthtech
Global coverage: FundingData